International Current Deferred Revenue from 2010 to 2024

IBT Stock   704.00  4.00  0.57%   
International Biotechnology's Current Deferred Revenue is decreasing over the years with slightly volatile fluctuation. Overall, Current Deferred Revenue is projected to go to about -27.6 M this year. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
-29.1 M
Current Value
-27.6 M
Quarterly Volatility
12.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check International Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among International Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 2.3 M, Selling General Administrative of 1.1 M or Total Revenue of 21.1 M, as well as many indicators such as . International financial statements analysis is a perfect complement when working with International Biotechnology Valuation or Volatility modules.
  
This module can also supplement various International Biotechnology Technical models . Check out the analysis of International Biotechnology Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in International Stock

International Biotechnology financial ratios help investors to determine whether International Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in International with respect to the benefits of owning International Biotechnology security.